These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38627298)

  • 1. Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials.
    Hamad AA; Amer BE
    Neurol Sci; 2024 Jul; 45(7):3503-3507. PubMed ID: 38627298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
    Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
    Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.
    Hamad AA; Amer BE; Hawas Y; Mabrouk MA; Meshref M
    Neurol Sci; 2024 May; 45(5):1861-1873. PubMed ID: 38105307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.
    Mora JS; Genge A; Chio A; Estol CJ; Chaverri D; Hernández M; Marín S; Mascias J; Rodriguez GE; Povedano M; Paipa A; Dominguez R; Gamez J; Salvado M; Lunetta C; Ballario C; Riva N; Mandrioli J; Moussy A; Kinet JP; Auclair C; Dubreuil P; Arnold V; Mansfield CD; Hermine O;
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):5-14. PubMed ID: 31280619
    [No Abstract]   [Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Masitinib for the treatment of Alzheimer's disease.
    Ettcheto M; Cano A; Sanchez-López E; Verdaguer E; Folch J; Auladell C; Camins A
    Neurodegener Dis Manag; 2021 Aug; 11(4):263-276. PubMed ID: 34412534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
    Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
    Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
    Deplanque G; Demarchi M; Hebbar M; Flynn P; Melichar B; Atkins J; Nowara E; Moyé L; Piquemal D; Ritter D; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Hammel P
    Ann Oncol; 2015 Jun; 26(6):1194-1200. PubMed ID: 25858497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Yang Y; Sun Y; Gao B; Wang Z; Chen Z; Wang Z
    CNS Drugs; 2020 Oct; 34(10):1015-1024. PubMed ID: 32857291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
    Vermersch P; Benrabah R; Schmidt N; Zéphir H; Clavelou P; Vongsouthi C; Dubreuil P; Moussy A; Hermine O
    BMC Neurol; 2012 Jun; 12():36. PubMed ID: 22691628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
    Dubois B; López-Arrieta J; Lipschitz S; Doskas T; Spiru L; Moroz S; Venger O; Vermersch P; Moussy A; Mansfield CD; Hermine O; Tsolaki M;
    Alzheimers Res Ther; 2023 Feb; 15(1):39. PubMed ID: 36849969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
    Lortholary O; Chandesris MO; Bulai Livideanu C; Paul C; Guillet G; Jassem E; Niedoszytko M; Barete S; Verstovsek S; Grattan C; Damaj G; Canioni D; Fraitag S; Lhermitte L; Georgin Lavialle S; Frenzel L; Afrin LB; Hanssens K; Agopian J; Gaillard R; Kinet JP; Auclair C; Mansfield C; Moussy A; Dubreuil P; Hermine O
    Lancet; 2017 Feb; 389(10069):612-620. PubMed ID: 28069279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect and Safety of 5-HT
    Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
    Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term efficacy and safety of lasmiditan, a novel 5-HT
    Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
    J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007744. PubMed ID: 25340915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
    Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
    Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
    Humbert M; de Blay F; Garcia G; Prud'homme A; Leroyer C; Magnan A; Tunon-de-Lara JM; Pison C; Aubier M; Charpin D; Vachier I; Purohit A; Gineste P; Bader T; Moussy A; Hermine O; Chanez P
    Allergy; 2009 Aug; 64(8):1194-201. PubMed ID: 19614621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.